Jane E. Staunton
Harvard University · 21 works · 7,911 citations · h-index 14
Top works
- Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses
- MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia
- Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia
- Chemosensitivity prediction by transcriptional profiling
- Synergistic drug combinations tend to improve therapeutically relevant selectivity
- Caenorhabditis elegans rab-3Mutant Synapses Exhibit Impaired Function and Are Partially Depleted of Vesicles
- aex-3 Encodes a Novel Regulator of Presynaptic Activity in C. elegans
- Adult male-specific and neonatally programmed rat hepatic P-450 forms RLM2 and 2a are not dependent on pulsatile plasma growth hormone for expression.
- seid Cells Efficiently Integrate Hairpin and Linear DNA Substrates
- V(D)J Recombination: Double‐Strand Break Repair Gene Products Used in the Joining Mechanism
- Rabphilin Potentiates SolubleN-Ethylmaleimide Sensitive Factor Attachment Protein Receptor Function Independently of rab3
- scid cells efficiently integrate hairpin and linear DNA substrates.
- Erratum: Synergistic drug combinations tend to improve therapeutically relevant selectivity
- Identification of Synergistic Combinations of F508del Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators
- Optimization of a Yellow Fluorescent Protein-Based Iodide Influx High-Throughput Screening Assay for Cystic Fibrosis Transmembrane Conductance Regulator ( CFTR ) Modulators
- Abstract CT142: TALAVE: Induction talazoparib (tala) followed by combined tala and avelumab in patients (pts) with advanced breast cancer (ABC)
- Dissection of cancer therapy combinations in RTK driven tumors using zotatifin (eFT226), a potent and selective eIF4A inhibitor
- 885 Characterization of the tumor microenvironment in advanced breast cancer patients treated with talazoparib followed by combination of talazoparib and avelumab
- TALAVE in Breast Cancer: BRCA1/2 Mutation-Dependent Immune Remodeling after PARP Inhibition with Limited Checkpoint Engagement
- Studies on tryptophan side chain oxidase